More about

Kidney Cancer

News
September 25, 2022
1 min read
Save

ESMO presentations highlight advances in kidney cancer, melanoma, lung cancer

ESMO presentations highlight advances in kidney cancer, melanoma, lung cancer

This year’s European Society for Medical Oncology Congress featured potentially practice-changing research in kidney cancer, cutaneous squamous cell carcinoma, lung cancer and melanoma.

News
September 12, 2022
2 min read
Save

Cabozantinib regimen ‘beat the doublet in PFS’ in untreated advanced kidney cancer

Cabozantinib regimen ‘beat the doublet in PFS’ in untreated advanced kidney cancer

Cabozantinib plus nivolumab and ipilimumab conferred a significant PFS benefit vs. nivolumab and ipilimumab alone among patients with advanced renal cell carcinoma, according to results of the COSMIC-313 trial presented at ESMO Congress.

News
August 22, 2022
2 min read
Save

Major adverse cardiovascular event risk higher with targeted therapies for kidney cancer

Major adverse cardiovascular event risk higher with targeted therapies for kidney cancer

Targeted cancer therapy had a higher association with risk for major adverse cardiovascular events than cytokine therapy among patients with advanced renal cell carcinoma, according to study results.

News
August 17, 2022
2 min read
Save

Acceptance of Medicaid varies greatly among cancer care facilities

Acceptance of Medicaid varies greatly among cancer care facilities

Although the number of Americans insured through Medicaid has increased during the past decade, barriers to cancer care access exist among Medicaid beneficiaries across high-quality centers, according to study results in JAMA Network Open.

News
July 29, 2022
1 min read
Save

Nivolumab-ipilimumab fails to show DFS benefit for certain patients with kidney cancer

Part A of a phase 3 trial assessing adjuvant nivolumab and ipilimumab for certain patients with renal cell carcinoma failed to meet the primary endpoint of DFS, according to topline data released by the agents’ manufacturer.

News
July 24, 2022
1 min read
Save

MD Anderson appoints division head of pathology and laboratory medicine

MD Anderson appoints division head of pathology and laboratory medicine

Donna Hansel, MD, PhD, has been named division head of pathology and laboratory medicine at The University of Texas MD Anderson Cancer Center.

News
June 22, 2022
3 min read
Save

Quality of life associated with survival in RCC

CHICAGO — Better health-related quality of life was linked to longer survival in patients with intermediate- or poor-risk renal cell carcinoma, according to an analysis of the CheckMate 214 trial.

News
May 12, 2022
3 min watch
Save

VIDEO: "Nurses need to be comfortable" managing kidney cancer immunotherapy side effects

VIDEO: "Nurses need to be comfortable" managing kidney cancer immunotherapy side effects

In this video, Nancy Moldawer, RN, MSN, discussed new treatments in kidney cancer and how to apply nursing strategies to best meet the needs of patients with renal cell carcinoma.

News
April 04, 2022
1 min watch
Save

VIDEO: KEYNOTE-564 'critical trial' in kidney cancer

VIDEO: KEYNOTE-564 'critical trial' in kidney cancer

Sumanta K. Pal, MD, co-director of Kidney Cancer Program at City of Hope, and a HemOnc Today Editorial Board Member, spoke with Healio about studies on renal cell carcinoma presented at the 2022 ASCO Genitourinary Cancers Symposium.

News
April 04, 2022
1 min watch
Save

VIDEO: Study assessing cytoreductive nephrectomy in the 'immune checkpoint era'

VIDEO: Study assessing cytoreductive nephrectomy in the 'immune checkpoint era'

In this video, Mark W. Ball, MD, discusses the ongoing SWOG S1931 study assessing the use of immune checkpoint inhibitors with or without cytoreductive nephrectomy in patients with renal cell carcinoma.

View more